Combined Chemotherapy and PD-1 Antibody(SHR-1210) With or Without Low-dose Decitabine Priming for Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL):Two Stage, Phase I/II Trail
Phase of Trial: Phase I/II
Latest Information Update: 06 Dec 2018
Price : $35 *
At a glance
- Drugs Camrelizumab (Primary) ; Decitabine (Primary) ; Doxorubicin; Gemcitabine; Vinorelbine
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 29 Nov 2018 Treatment arms has been changed fro 2 to 1 and study design has been changed from Parallel Assignment to Single Group Assignment.
- 29 Nov 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
- 29 Nov 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Mar 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History